Literature DB >> 19904524

Characterization of an O-desmethylangolensin-producing bacterium isolated from human feces.

Shin-ichiro Yokoyama1, Toshio Niwa, Toshihiko Osawa, Tohru Suzuki.   

Abstract

A bacterium that converted daidzein to O-desmethylangolensin was isolated from the feces of healthy humans. It was an obligately anaerobic, nonsporeforming, nonmotile and Gram-positive rod. The isolate used glucose, sucrose, raffinose, maltose, and fructose as carbon sources. It did not hydrolyze gelatin, esculin, or starch. The strain was urease, acid phosphatase, and arginine dihydrolase positive. It was catalase, oxidase, H(2)S, and indole negative. The major products of glucose fermentation were butyrate and lactate. Its mol% G+C was 51.2. The major cellular fatty acids were C(16:0) DMA, C(16:0), and C(16:0) aldehyde. The structural type of cell wall peptidoglycan was suggested to be A1gamma. The isolate was susceptible to beta-lactam, cefem, and macrolide antibiotics and resistant to aminoglycoside and quinolone antibiotics. The bacterium was related to Eubacterium ramulus ATCC29099(T), Eubacterium rectale ATCC33656(T), and species of the genus Roseburia, but the highest 16S rRNA gene similarity to these described species was only 94.4%, consistent with its being classified as a novel genus. Based on the above, the isolate, named strain SY8519, was identified as belonging to a novel genus in the Clostridium rRNA cluster XIVa.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19904524     DOI: 10.1007/s00203-009-0524-5

Source DB:  PubMed          Journal:  Arch Microbiol        ISSN: 0302-8933            Impact factor:   2.552


  10 in total

1.  Complete genomic sequence of the O-desmethylangolensin-producing bacterium Clostridium rRNA cluster XIVa strain SY8519, isolated from adult human intestine.

Authors:  Shin-ichiro Yokoyama; Kenshiro Oshima; Izumi Nomura; Masahira Hattori; Tohru Suzuki
Journal:  J Bacteriol       Date:  2011-10       Impact factor: 3.490

Review 2.  Bacterial species involved in the conversion of dietary flavonoids in the human gut.

Authors:  Annett Braune; Michael Blaut
Journal:  Gut Microbes       Date:  2016-03-10

3.  Metabolomics profiles of premenopausal women are different based on O-desmethylangolensin metabotype.

Authors:  Cara L Frankenfeld; Gertraud Maskarinec; Adrian A Franke
Journal:  Br J Nutr       Date:  2021-11-12       Impact factor: 4.125

4.  An NADH-Dependent Reductase from Eubacterium ramulus Catalyzes the Stereospecific Heteroring Cleavage of Flavanones and Flavanonols.

Authors:  Annett Braune; Michael Gütschow; Michael Blaut
Journal:  Appl Environ Microbiol       Date:  2019-09-17       Impact factor: 4.792

Review 5.  O-desmethylangolensin: the importance of equol's lesser known cousin to human health.

Authors:  Cara L Frankenfeld
Journal:  Adv Nutr       Date:  2011-06-28       Impact factor: 8.701

Review 6.  Isoflavones and inflammatory bowel disease.

Authors:  Ze-Yu Wu; Li-Xuan Sang; Bing Chang
Journal:  World J Clin Cases       Date:  2020-06-06       Impact factor: 1.337

Review 7.  Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review.

Authors:  Aleksandra Duda-Chodak; Tomasz Tarko; Paweł Satora; Paweł Sroka
Journal:  Eur J Nutr       Date:  2015-02-12       Impact factor: 5.614

8.  Fecal bacterial community changes associated with isoflavone metabolites in postmenopausal women after soy bar consumption.

Authors:  Cindy H Nakatsu; Arthur Armstrong; Andrea P Clavijo; Berdine R Martin; Stephen Barnes; Connie M Weaver
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

Review 9.  Beneficial Effects of Phenolic Compounds on Gut Microbiota and Metabolic Syndrome.

Authors:  Kamila Kasprzak-Drozd; Tomasz Oniszczuk; Mateusz Stasiak; Anna Oniszczuk
Journal:  Int J Mol Sci       Date:  2021-04-02       Impact factor: 5.923

Review 10.  Gut microbiota: a new angle for traditional herbal medicine research.

Authors:  Longfei Lin; Liyu Luo; Ming Zhong; Tanggui Xie; Yuling Liu; Hui Li; Jian Ni
Journal:  RSC Adv       Date:  2019-06-07       Impact factor: 4.036

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.